Michael Unterhalt, MD, on Mantle Cell Lymphoma: Long-Term Follow-up Results
2017 ASH Annual Meeting
Michael Unterhalt, MD, of the University Hospital Grosshadern, discusses study findings on rituximab maintenance after first-line immunochemotherapy among older patients who are not candidates for autologous stem cell transplantation (Abstract 153).
Jakub Svoboda, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses some encouraging phase I/II results on brentuximab vedotin with R-CHP chemotherapy as front-line treatment of CD30-positive primary mediastinal large B-cell, diffuse large B-cell, and gray zone lymphomas (Abstract 191).
Joseph M. Connors, MD, of the British Columbia Cancer Agency, discusses study findings on a new front-line option: brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with previously untreated stage III or IV Hodgkin lymphoma (Abstract 6).
Maria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, discusses phase III study findings on daratumumab plus bortezomib, melphalan, and prednisone vs bortezomib, melphalan, and prednisone in patients ineligible for transplant who have been newly diagnosed with multiple myeloma (Abstract LBA-4).
Carla Casulo, MD, of the James P. Wilmot Cancer Center, discusses findings on POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma, using data from more than 5,000 patients in 13 clinical trials (Abstract 412).
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephen J. Schuster, MD, of the Abramson Cancer Center, University of Pennsylvania, discuss phase II findings on tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma (Abstract 577).